HAEM5:Classic Hodgkin lymphoma: Difference between revisions

(View all pending changes)

[pending revision]

← Older edit Newer edit →

VisualWikitext

@@ Line 68: / Line 68: @@
 |
 |}
-No characteristic chromosomal rearrangements have been reported for lymphocyte-rich classical Hodgkin's lymphoma.
 ==Individual Region Genomic Gain/Loss/LOH==
@@ Line 86: / Line 84: @@
 |P
 |No
-|REL amplification promotes NF-κB signaling activation (PMID: 19380639)
+|REL amplification promotes NF-κB signaling activation <ref name=":0">{{Cite journal|last=Schmitz|first=Roland|last2=Hansmann|first2=Martin-Leo|last3=Bohle|first3=Verena|last4=Martin-Subero|first4=Jose Ignacio|last5=Hartmann|first5=Sylvia|last6=Mechtersheimer|first6=Gunhild|last7=Klapper|first7=Wolfram|last8=Vater|first8=Inga|last9=Giefing|first9=Maciej|date=2009-05-11|title=TNFAIP3 (A20) is a tumor suppressor gene in Hodgkin lymphoma and primary mediastinal B cell lymphoma|url=https://pubmed.ncbi.nlm.nih.gov/19380639|journal=The Journal of Experimental Medicine|volume=206|issue=5|pages=981–989|doi=10.1084/jem.20090528|issn=1540-9538|pmc=2715030|pmid=19380639}}</ref>
 |-
 |9p
@@ Line 94: / Line 92: @@
 |T, P
 |Yes (PMID:20628145)
-|9p24.1 amplification drives PD-L1/PD-L2 overexpression, relevant for immune checkpoint inhibitor therapy (PMID: 20628145, 27069084)
+|9p24.1 amplification drives PD-L1/PD-L2 overexpression, relevant for immune checkpoint inhibitor therapy <ref>{{Cite journal|last=Green|first=Michael R.|last2=Monti|first2=Stefano|last3=Rodig|first3=Scott J.|last4=Juszczynski|first4=Przemyslaw|last5=Currie|first5=Treeve|last6=O'Donnell|first6=Evan|last7=Chapuy|first7=Bjoern|last8=Takeyama|first8=Kunihiko|last9=Neuberg|first9=Donna|date=2010-10-28|title=Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma|url=https://pubmed.ncbi.nlm.nih.gov/20628145|journal=Blood|volume=116|issue=17|pages=3268–3277|doi=10.1182/blood-2010-05-282780|issn=1528-0020|pmc=2995356|pmid=20628145}}</ref><ref>{{Cite journal|last=Roemer|first=Margaretha G. M.|last2=Advani|first2=Ranjana H.|last3=Ligon|first3=Azra H.|last4=Natkunam|first4=Yasodha|last5=Redd|first5=Robert A.|last6=Homer|first6=Heather|last7=Connelly|first7=Courtney F.|last8=Sun|first8=Heather H.|last9=Daadi|first9=Sarah E.|date=2016-08-10|title=PD-L1 and PD-L2 Genetic Alterations Define Classical Hodgkin Lymphoma and Predict Outcome|url=https://pmc.ncbi.nlm.nih.gov/articles/PMC5019753/|journal=Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology|volume=34|issue=23|pages=2690–2697|doi=10.1200/JCO.2016.66.4482|issn=1527-7755|pmc=5019753|pmid=27069084}}</ref>
 |-
 |17p
@@ Line 102: / Line 100: @@
 |P
 |No
-|MAP3K14 (NIK) gain activates alternative NF-κB signaling (PMID: 19380639)
+|MAP3K14 (NIK) gain activates alternative NF-κB signaling <ref name=":0" />
 |-
 |6q
@@ Line 110: / Line 108: @@
 |P
 |No
-|Loss of TNFAIP3 (A20) disrupts NF-κB regulation (PMID: 19380639)
+|Loss of TNFAIP3 (A20) disrupts NF-κB regulation <ref name=":0" />
 |}
-There is no typical findings for lymphocyte-rich classical Hodgkin's lymphoma, the main features are also seen in other classical Hodgkin's lymphoma subtypes.
+The table below seems duplicated, can be deleted?
 {| class="wikitable sortable"
@@ Line 335: / Line 333: @@
 ==Genes and Main Pathways Involved==
-N/A
 {| class="wikitable sortable"
 |-